MedPath

SeaStar Medical Focuses on Hyperinflammation Therapies for Critical Illnesses

• SeaStar Medical is developing extracorporeal therapies to mitigate hyperinflammation's effects on vital organs, targeting effector cells responsible for systemic inflammation. • The company's core business revolves around advanced renal therapy systems designed to reduce cytokine storms in severe infections and autoimmune diseases. • Clinical trials have demonstrated the efficacy of SeaStar Medical's therapies in reducing inflammation and improving patient outcomes, positioning them as a promising investment in medical technology. • SeaStar Medical's therapies are useful in conditions with severe inflammatory responses, such as infections and autoimmune diseases.

SeaStar Medical Holding Corporation (ICU) is advancing medical technology focused on mitigating the adverse effects of hyperinflammation on vital organs. The company specializes in creating and commercializing extracorporeal therapies that specifically target effector cells responsible for systemic inflammation, which often leads to direct tissue damage and the secretion of pro-inflammatory cytokines, triggering imbalanced immune responses.

Core Business and Technology

SeaStar Medical's core business revolves around innovative treatments designed to alleviate intense inflammatory responses seen in various medical conditions. Their primary product offerings include advanced renal therapy systems that aim to reduce the impact of cytokine storms, often observed in severe cases of infections and autoimmune diseases. These extracorporeal therapies involve treating blood outside the body to remove harmful substances like pro-inflammatory cytokines.

Clinical Achievements and R&D

One of the company’s notable achievements includes successful clinical trials demonstrating the efficacy of their therapies in reducing inflammation and improving patient outcomes. SeaStar Medical is currently engaged in several research and development projects to expand the application of their therapies across multiple medical disciplines. The company collaborates with various healthcare providers and research institutions to enhance their product development and distribution.

Financial Position and Strategic Partnerships

SeaStar Medical Holding Corp is strategically positioned with partnerships that enhance their research capabilities and product distribution. The company is committed to advancing its technology through continuous innovation and maintaining strong relationships with healthcare providers and patients. As of October 25, 2024, the stock price of SeaStar Medical Holding Corporation (ICU) is $3.624, with a market cap of approximately $15.0 million.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves SeaStar Medical's SCD-ADULT Feasibility Study for Cardiorenal Syndrome

The FDA has approved SeaStar Medical's IDE application for SCD-ADULT to assess safety and efficacy in reducing inflammation in adults with acute heart failure.
The feasibility study will enroll 20 patients across up to five clinical sites, supported by a $3.6 million NIH grant to Innovative BioTherapies.

SeaStar Medical's Selective Cytopheretic Device Receives FDA Breakthrough Designation for ESRD Inflammation

SeaStar Medical's Selective Cytopheretic Device (SCD) has been granted Breakthrough Device designation by the FDA for treating inflammation in end-stage renal disease (ESRD).
The SCD targets and neutralizes pro-inflammatory cytokines, aiming to mitigate hyperinflammation and improve clinical outcomes in ESRD patients.

SeaStar Medical's SCD Receives FDA Breakthrough Designation for Chronic Dialysis

SeaStar Medical's Selective Cytopheretic Device (SCD) has received its fourth FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease patients undergoing chronic hemodialysis.
The designation expands SeaStar Medical's addressable U.S. patient population to 745,000 annually, targeting over 480,000 individuals requiring in-center hemodialysis.

SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for ESRD Treatment

SeaStar Medical's SCD device receives FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing hemodialysis.
The SCD targets dysregulated immune responses, aiming to improve survival rates and quality of life for over 480,000 chronic hemodialysis patients in the U.S.

SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for Chronic Dialysis

SeaStar Medical's Selective Cytopheretic Device (SCD) has received Breakthrough Device Designation from the FDA for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis.
This marks the fourth Breakthrough Device Designation for the SCD, expanding the addressable patient population to at least 745,000 annually in the U.S., according to SeaStar Medical.

SeaStar Medical Advances AKI Trial with New Site Activations and Enrollment Milestones

SeaStar Medical activated its 14th clinical site for the NEUTRALIZE-AKI pivotal trial, evaluating the Selective Cytopheretic Device (SCD) in adult patients with acute kidney injury (AKI).
The NEUTRALIZE-AKI trial has enrolled 76 of the planned 200 subjects, with an interim analysis expected by mid-2025 based on the first 100 subjects.

Immunocore and Bristol Myers Squibb Collaborate on Phase 3 Trial for Advanced Cutaneous Melanoma

Immunocore partners with Bristol Myers Squibb to evaluate IMC-F106C plus nivolumab in a Phase 3 trial for advanced cutaneous melanoma.
IMC-F106C is an ImmTAC bispecific TCR candidate designed to target and destroy diseased cells by harnessing the body's immune system.

FDA Grants SeaStar Medical's Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation has received its third Breakthrough Device Designation from the FDA for its Selective Cytopheretic Device (SCD), aimed at treating patients with acute kidney injury and acute on chronic liver failure in the ICU. This designation is expected to accelerate the clinical development and regulatory review of the SCD for hepatorenal syndrome, a condition with a high mortality rate. Positive outcomes from a pilot study at the University of Michigan suggest the SCD's potential in improving patient outcomes as a bridge to liver transplantation.

SeaStar Medical Receives FDA Approval to Begin Study

SeaStar Medical, a medical technology company, has received FDA approval to start a study on its extracorporeal therapies aimed at reducing inflammation's impact on vital organs in critically ill patients.

SeaStar Medical Receives FDA Breakthrough Device Designation for Novel Therapy

SeaStar Medical has been granted a Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device (SCD), aimed at treating acute kidney injury (AKI) in adults. This designation facilitates an expedited regulatory review for the upcoming pivotal clinical trial of the SCD, which targets hyperinflammation by selectively addressing activated neutrophils and monocytes.

Reference News

[1]
ICU - SeaStar Medical Holding Corporation Latest Stock News & Market Updates
stocktitan.net · Oct 27, 2024

SeaStar Medical Holding Corp (ICU) develops proprietary solutions to mitigate hyperinflammation's adverse effects on vit...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy